Table 1.

Antiproliferation activity of synthesized compounds 32–54 in the MDA-MB-231, MCF-7 and Hs578T breast cancer cell lines as well as against normal human fibroblast cell line. Selectivity index values are also provided for each IC₅₀ value.

Compound	IC50 (μM)				Selectivity Index for
	MDA-MB-231	MCF-7	Hs578T	Fibroblasts	MDA-MB-231	MCF-7	Hs578T
31	>75	23.90 ± 4.47	>75	n/a	n/a	n/a	n/a
32	>75	>75	>75	n/a	n/a	n/a	n/a
33	5.89 ± 0.77	2.21 ± 0.40	2.48 ± 0.13	8.68 ± 0.88	1.47	3.93	3.50
34	>75	21.36 ± 0.60	28.09 ± 7.76	n/a	n/a	n/a	n/a
35	37.05 ± 1.82	9.90 ± 0.05	8.69 ± 0.55	33.83 ± 6.63	0.91	3.42	3.89
36	>75	>75	>75	n/a	n/a	n/a	n/a
37	>75	11.39 ± 1.55	>75	n/a	n/a	n/a	n/a
38	73.00 ± 2.31	7.06 ± 1.71	>75	160.65 ± 13.08	2.20	22.75	-
39	>75	11.50 ± 1.02	15.71 ± 2.74	32.88 ± 2.27	-	2.86	2.09
40	>75	>75	>75	92.11 ± 5.47	-	-	-
41	7.12 ± 0.20	3.99 ± 0.15	10.31 ± 0.25	7.96 ± 0.10	1.12	1.99	0.77
42	>75	37.01 ± 6.89	43.33 ± 4.32	n/a	n/a	n/a	n/a
43	29.20 ± 3.26	4.29 ± 0.29	16.64 ± 2.83	33.05 ± 6.10	1.13	7.70	1.99
44	25.21 ± 0.84	3.45 ± 0.36	21.48 ± 1.20	44.03 ± 1.84	1.75	12.76	2.05
45	>75	29.94 ± 5.26	>75	n/a	n/a	n/a	n/a
46	>75	>75	>75	n/a	n/a	n/a	n/a
47	40.37 ± 0.67	12.52 ± 8.43	>75	n/a	n/a	n/a	n/a
48	>75	25.62 ± 0.09	23.15 ± 2.50	n/a	n/a	n/a	n/a
49	22.43 ± 0.81	45.93 ± 1.52	17.07 ± 2.13	23.81 ± 1.07	1.06	0.52	1.39
50	>75	>75	>75	192.25 ± 51.41	-	-	-
51	18.01 ± 2.78	>75	23.11 ± 0.04	20.47 ± 2.46	1.14	-	0.88
52	>75	>75	60.21 ± 6.94	n/a	n/a	n/a	n/a
53	17.12 ± 0.41	41.44 ± 1.74	28.44 ± 1.97	n/a	n/a	n/a	n/a
28	115.44 ± 40.11	206.95 ± 7.28	135.95 ± 2.47	n/a	n/a	n/a	n/a
5-FU	19.17 ± 0.39	5.37 ± 1.16	7.38 ± 2.49	9.43 ± 0.80	0.49	1.76	1.28